HealthDay News — Vital wheat gluten (VWG) oral immunotherapy (OIT) induces desensitization in about half of patients with wheat allergy after a year of treatment, according to a study published online Oct. 30 in the Journal of Allergy and Clinical Immunology.

Anna Nowak-Wegrzyn, MD, PhD, from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues randomly assigned 46 patients with wheat allergy to low-dose VWG OIT or placebo after a baseline double-blind, placebo-controlled food challenge, with biweekly escalation to 1445 mg of wheat protein (WP). Active participants continued low-dose VWG OIT for another year; participants treated with placebo crossed over to high-dose VWG OIT.

The researchers found that in both groups, the median baseline successfully consumed dose (SCD) was 43 mg of WP. At year one, 52.2% and 0%, respectively, of the 23 VWG OIT-treated and 23 placebo-treated participants achieved the primary end point of an SCD of ≥4443 mg of WP; the median SCDs were 4443 and 143 mg, respectively. Overall, 30.4% of the 23 low-dose VWG OIT-treated participants were desensitized to an SCD of 7443 mg of WP at year two; at 8 to 10 weeks off therapy, 13% achieved sustained unresponsiveness. Of the placebo-treated participants who were crossed over to high-dose VWG OIT, 57.1 percent were desensitized after one year.

Related Articles

“Overall, we were very pleased with the efficacy and safety of wheat oral immunotherapy for highly allergic patients,” Nowak-Wegrzyn said in a statement.

Several authors disclosed ties to pharmaceutical, food, and medical technology companies, including Thermo Fisher Scientific, which partially funded the study.

Abstract/Full Text (subscription or payment may be required)